最新ニュース HeartBeam (NASDAQ:BEAT) 株価情報

HeartBeam

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

HeartBeam Inc

News

Offerings

BEAT

HeartBeam Prices $10.0M Underwritten Public Offering Of  5,882,353 Shares At $1.70/Share

Heartbeam Has Submitted A 510(K) Application To The U.S. Food And Drug Administration For The Company's  12-Lead Electrocardiogram Synthesis Software Designed For The Assessment Of Rhythms And Arrhythmias

Heartbeam Filed For Common Stock Offering Of Up To $10M

WIIM

Heartbeam shares are trading lower amid a possible selloff. The stock initially traded higher after the company announced FDA clearance for its HeartBeam system, but it has since reversed.

General

HeartBeam shares are trading higher after the FDA granted the company 510(k) clearance of its system for comprehensive arrhythmia assessment.

HeartBeam Announced FDA Clearance For Its HeartBeam System For Comprehensive Arrhythmia Assessment

Biotech

HeartBeam Unveils Data At AHA 2024 For Portable Credit Card-Sized ECG Device; Studies Demonstrate Comparable Arrhythmia Detection To Standard ECGs And Highlight Remote Chest Pain Evaluation To Reduce Heart Attack Care Delays

Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) with a Speculative Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent.

Earnings

Earnings Misses

HeartBeam Q3 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

Management

HeartBeam Appoints Robert Eno As CEO To Lead U.S. Commercialization Efforts, While Founder Branislav Vajdic Transitions To President To Focus On Advancing Vector-Based Technology And AI Applications For Heart Health

HeartBeam Appoints Timothy Cruickshank As Chief Financial Officer, Effective Immediately

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year.

HeartBeam Q2 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54089132&amp;newsitemid=20240701576961&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=a8e16bb73468ac62714a82d6f6ae9bb7">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap&#xAE; Index effective after the market close on June 28, 2024 as part of FTSE Russell's annual reconstitution.

HeartBeam Added To Russell Microcap Index

New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company's AI Program
Data Show That Applying AI to VCG Data Provides More Consistent and Reliable Detection of Atrial Flutter

HeartBeam's Study Demonstrates AI Algorithm Combined with Vectorcardiography Outperforms Panel Of Cardiologists in Detecting Arrhythmias

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 66 percent increase over losses of $(0.50) per share from the same period last year.

HeartBeam Q1 2024 GAAP EPS $(0.17) Misses $(0.15) Estimate

<h3>Gainers</h3>
<ul>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares moved upwards by 7.17% to $1.06. The company's market cap stands at $3.8 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) shares moved upwards by 6.72% to $0.2. The market value of their outstanding shares is at $10.7 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares rose 5.85% to $0.77. The company's market cap stands at $5.2 million. </li>
<li>Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) shares increased by 5.43% to $0.25. The company's market cap stands at $69.1 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock rose 5.24% to $0.91. The market value of their outstanding shares is at $2.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) shares declined by 16.4% to $0.12 during Friday's after-market session. The company's market cap stands at $3.5 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) stock decreased by 10.36% to $1.98. The company's market cap stands at $52.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares decreased by 6.71% to $0.3. The market value of their outstanding shares is at $3.0 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 5.04% to $7.35. The company's market cap stands at $6.2 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares fell 5.0% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 5.0% to $0.69. The company's market cap stands at $12.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AFIB

ALZN

APVO

ASXC

GRTX

MBIO

MNPR

NBSE

PALI

TRVN

YCBD

12 Health Care Stocks Moving In Friday's After-Market Session

New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company's Deep Learning Technology
Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables

HeartBeam Presents Results On AI Capabilities For Detecting Arrhythmias

Press Releases

HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

Lifesaving Portable, AI Augmented Cardiac Monitoring Technology Poised for Commercial Launch Under New Industry Leader CEO: Heartbeam, Inc. (NASDAQ: BEAT)

HeartBeam Named "Rising Star" at the 6th Annual Digital Health Hub Foundation Awards

HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time

HeartBeam Reports Third Quarter 2024 Results

HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference

HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock

Apyx Medical

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

Daxor

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

HeartBeam

ニュース

最新ニュース HeartBeam (NASDAQ:BEAT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル